Literature DB >> 22392098

In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.

V Karthick1, V Shanthi, R Rajasekaran, K Ramanathan.   

Abstract

The recent H1N1 influenza pandemic has attracted worldwide attention due to the high infection rate. Oseltamivir is a new class of anti-viral agent approved for the treatment and prevention of influenza infections. The principal target for this drug is a virus surface glycoprotein, neuraminidase (NA), which facilitates the release of nascent virus and thus spreads infection. Until recently, only a low prevalence of neuraminidase inhibitor (NAI) resistance (<1 %) had been detected in circulating viruses. However, there have been reports of significant numbers of A (H1N1) influenza strains with a N294S neuraminidase mutation that was highly resistant to the NAI, oseltamivir. Hence, in the present study, we highlight the effect of point mutation-induced oseltamivir resistance in H1N1 subtype neuraminidases by molecular simulation approach. The docking analysis reveals that mutation (N294S) significantly affects the binding affinity of oseltamivir with mutant type NA. This is mainly due to the decrease in the flexibility of binding site residues and the difference in prevalence of hydrogen bonds in the wild and mutant structures. This study throws light on the possible effects of drug-resistant mutations on the large functionally important collective motions in biological systems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392098     DOI: 10.1007/s00709-012-0394-6

Source DB:  PubMed          Journal:  Protoplasma        ISSN: 0033-183X            Impact factor:   3.356


  41 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Implications of protein flexibility for drug discovery.

Authors:  Simon J Teague
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

3.  ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement.

Authors:  Karsten Suhre; Yves-Henri Sanejouand
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

4.  Oseltamivir resistance--disabling our influenza defenses.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

5.  Prediction of protein B-factor profiles.

Authors:  Zheng Yuan; Timothy L Bailey; Rohan D Teasdale
Journal:  Proteins       Date:  2005-03-01

6.  A complete small molecule dataset from the protein data bank.

Authors:  Howard J Feldman; Kevin A Snyder; Amy Ticoll; Greg Pintilie; Christopher W V Hogue
Journal:  FEBS Lett       Date:  2006-02-17       Impact factor: 4.124

7.  Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.

Authors:  Shu-Qing Wang; Qi-Shi Du; Kou-Chen Chou
Journal:  Biochem Biophys Res Commun       Date:  2007-01-19       Impact factor: 3.575

Review 8.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

9.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.

Authors:  J N Varghese; P W Smith; S L Sollis; T J Blick; A Sahasrabudhe; J L McKimm-Breschkin; P M Colman
Journal:  Structure       Date:  1998-06-15       Impact factor: 5.006

10.  Analysis of a point mutation in H5N1 avian influenza virus hemagglutinin in relation to virus entry into live mammalian cells.

Authors:  Yan Su; Huai-Yi Yang; Bao-Jiang Zhang; Hong-Ling Jia; Po Tien
Journal:  Arch Virol       Date:  2008-11-20       Impact factor: 2.574

View more
  3 in total

1.  Targeting a cluster of arginine residues of neuraminidase to avoid oseltamivir resistance in influenza A (H1N1): a theoretical study.

Authors:  L Ramírez-Salinas Gema; L E Tolentino-Lopez; F Martínez-Ramos; I Padilla-Martínez; J García-Machorro; J Correa-Basurto
Journal:  J Mol Model       Date:  2015-01-22       Impact factor: 1.810

2.  Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.

Authors:  Abida Batool; Nousheen Bibi; Farhat Amin; Mohammad Amjad Kamal
Journal:  Eur J Pharmacol       Date:  2020-12-01       Impact factor: 4.432

3.  Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization.

Authors:  Yingjie Zhang; Qiqi Liu; Dou Wang; Suhong Chen; Shengqi Wang
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.